头颈部鳞状细胞癌的靶向治疗研究进展

doi:10.6040/j.issn.1673-3770.0.2018.058

摘要/Abstract

摘要： 头颈部肿瘤是常见肿瘤之一,超过95%的病理类型是鳞状细胞癌,手术与放化疗结合的综合治疗方案是头颈部鳞状细胞癌(HNSCC)的主要治疗方案,但是总体生存率并不高,主要原因是肿瘤复发和/或转移;同时复发性或转移性HNSCC常无法进行手术治疗,放化疗效果也差。靶向治疗的发现为HNSCC、特别是复发性或转移性HNSCC的治疗提供了新的方法。为了进一步认识靶向治疗的临床治疗作用,就HNSCC的靶向治疗研究进展做一综述。

关键词: 头颈部鳞状细胞癌, 靶向治疗

Abstract: Head and neck cancer is one of the most common tumors in the world. More than 95% of all pathological types are squamous cell carcinomas. The combination of surgery and radiotherapy and chemotherapy is the widely accepted treatment for head and neck squamous cell carcinoma(HNSCC). However, the overall survival rate is low, mainly owing to tumor recurrence and/or metastasis. Meanwhile, in recurrent or metastatic HNSCC, surgery is often difficult. Moreover, the effect of radiotherapy and chemotherapy is also poor. The discovery of targeted therapy has provided a new approach for the treatment of HNSCCs, especially those that are recurrent or metastatic. To further understand the clinical therapeutic effect of targeted therapy, this article reviews the research progress of targeted therapy for HNSCC.

Key words: Targeted therapy, Head and neck squamous cell carcinoma

中图分类号:

R739.6

吴静,刘业海. 头颈部鳞状细胞癌的靶向治疗研究进展[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 97-102.

WU Jing, LIU Yehai. Targeted therapy for head and neck squamous cell carcinoma[J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(5): 97-102.

参考文献 33

[1]	Darío GC, Ángeles VM, Álvarez-Teijeiro Saúl, et al. Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas[J]. Oncotarget, 2016, 7(20):29780-29793.
[2]	吴春晓,鲍萍萍,黄哲宙,等. 2003-2012年上海市头颈部恶性肿瘤发病特征分析[J]. 中国癌症杂志, 2017, 27(6):406-414. WU Chunxiao, BAO Pingping, HUANG Zhezhou, et al. The patterns of head and neck cancer incidence in Shanghai from 2003 to 2012[J]. Chin Oncol, 27(6):406-414.
[3]	Vatte C, Al Amri AM, Cyrus C, et al. Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma[J]. Onco Targets Ther, 2017, 10:1527-1533. DOI: 10.2147/OTT.S132187. eCollection 2017.
[4]	Kondo N, Tsukuda M, Sakakibara A, et al. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines[J]. Int J Oncol, 2012, 40(6):1805-1812.
[5]	Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer[J]. N Engl J Med, 2008, 359(11):1116-1127.
[6]	Mesía R, Garcia-Saenz JA, Lozano A, et al. Could the addition of Cetuximab to conventional radiotherapy improve organ preservation in those patients with locally-advanced larynx cancer and who respond to induction chemotherapy? An organ preservation TTCC phase II study[J]. Int J Radiat Oncol Biol Phys, 2017, 97(3):473-480.
[7]	Stokes WA, Sumner WA, Breggren KL, et al. A comparison of concurrent cisplatin versus cetuximab with radiotherapy in locally-advanced head and neck cancer: A bi-institutional analysis[J]. Rep Pract Oncol Radiothe, 2017, 22(5):389-395.
[8]	Trivedi S, Srivastava RM, Conchabenavente F, et al. Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients[J]. Clin Cancer Res, 2016, 22(21):5229-5237.
[9]	Kruser TJ, Armstrong EA, Ghia AJ, et al. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 72(2):534-542.
[10]	Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck(SPECTRUM): an open-label phase 3 randomised trial[J]. Lancet Oncology, 2013, 14(8):697-710.
[11]	Kushwaha VS, Gupta S, Husain N, et al. Gefitinib,Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma[J]. Cancer Biol Ther, 2015, 16(2):346-351.
[12]	Vergez S, Delord JP, Thomas F, et al. Preclinical and clinical evidence that Deoxy-2-[18F] fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer[J]. Clin Cancer Res, 2010, 16(17):4434-4445.
[13]	Orcutt KP, Parsons AD, Sibenaller ZA, et al. Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4[J]. Cancer Res, 2011, 71(11):3932-3940.
[14]	Choong NW, Kozloff M, Taber D, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma[J]. Invest New Drugs, 2010, 28(5):677-683.
[15]	Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer[J]. Cancer Chemother Pharmacol, 2010, 65(4):649-660.
[16]	Kondo N, Tsukuda M, Ishiguro Y, et al. Antitumor effects of lapatinib(GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma[J]. Oncol Rep, 2010, 23(4):957-963.
[17]	Krishna SM, James S, Balaram P. Expression of VEGF as prognositic-cator in primary nasopharyngeal cancer and its relation to EBV status[J]. Virus Res, 2006, 115(1):85-90.
[18]	尹中普,杨琛. EndophilinⅡ和VEGF-C在喉癌组织中的表达及其与喉癌预后的关系[J]. 临床耳鼻咽喉头颈外科杂志, 2015,29(13):1156-1159. YIN Zhongpu, YANG Chen. The expression of endophilin II and VEGF-C in human laryngeal cancer and connection with clinical treatment[J]. J Clin Otorhinolaryngol Head Neck Surg, 2015, 29(13):1156-1159.
[19]	Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma(RTOG 0615): a phase 2 multi-institutional trial[J]. Lancet Oncology, 2012, 13(2):172-180.
[20]	Argiris A, Bauman JE, Ohr J, et al. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer[J]. Ann Oncol, 2016, 27(8):1594-1600.
[21]	Bonhin RG, de Carvalho GM, Guimarães AC, et al. Histologic correlation of VEGF and COX-2 expression with tumor size in squamous cell carcinoma of the larynx and hypopharynx[J]. Ear Nose Throat J, 2017, 96(4-5):176-182.
[22]	王智勇,成伟,梁中敏,等. 声门上型喉癌中环氧化酶-2的表达及与微血管和淋巴管密度的关系[J]. 中国肿瘤外科杂志, 2015, 7(1):27-29,32. WANG Zhiyong, CHEN Wei, LIANG Zhongmin, et al. The expression of COX-2 and its relationship with microvessel density and lymphatic vessel density in supraglottic laryngeal carcinoma[J]. Chin J Surg Onco, 2015, 7(1):27-29, 32.
[23]	Zhao YQ, Feng HW, Jia T, et al. Antiproliferative effects of celecoxib in Hep-2 cells through telomerase inhibition and induction of apoptosis[J]. Asian Pac J Cancer Prev, 2014, 15(12):4919-4923.
[24]	Zhang SX, Qiu QH, Chen WB, et al. Celecoxib enhances radiosensitivity via induction of G2-M phase arrest and apoptosis in nasopharyngeal carcinoma[J]. Cell Physiol Biochem, 2014, 33(5):1484-1497.
[25]	Chiang SL, Velmurugan BK, Chung CM, et al. Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma[J]. Sci Rep, 2017, 7(1):6235.
[26]	Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas[J]. Nature, 2015, 517(7536):576-582.
[27]	Wang B, Qin H, Wang Y, et al. Effect of DJ-1 overexpression on the proliferation, apoptosis, invasion and migration of laryngeal squamous cell carcinoma SNU-46 cells through PI3K/AKT/mTOR[J]. Oncol Rep, 2014, 32(3):1108-1116.
[28]	Wang KF, Yang H, Jiang WQ, et al. Puquitinib mesylate(XC-302)induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells[J]. Int J Mol Med, 2015, 36(6):1556-1562.
[29]	Fury MG, Sherman E, Ho AL, et al. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer[J]. Cancer, 2013, 119(10): 1823-1831.
[30]	Villaflor VM, Melotek JM, Karrison TG, et al. Response-adapted volume de-escalation(RAVD)in locally advanced head and neck cancer[J]. Ann Oncol, 2016, 27(5):908-913.
[31]	赵建夫, 陈文慧, 赵凤芝,等. bFGF和MMP9在鼻咽癌组织中的表达及其临床意义[J]. 中国病理生理杂志,2017,33(6):1006-1011. ZHAO Jianfu, CHEN Wenhui, ZHAO Fengzhi, et al. Expression and clinical significance of bFGF and MMP9 in nasopharyngeal carcinoma[J]. Chin J Pathophysiol, 2017, 33(6):1006-1011.
[32]	陈应超,王玮,李兆龙,等. MTDH和MMP-9在喉鳞状细胞癌组织中的表达及意义[J]. 临床耳鼻咽喉头颈外科杂志, 2016,30(1):60-63. CHEN Yingchao, WANG Wei, LI Zhaolong, et al. Expression and significance of MTDH and MMP-9 in Laryngeal squamous cell carcinoma[J]. J Clin Otorhinolaryngol Head Neck Surg, 2016, 30(1):60-63.
[33]	Luo S, Huang G, Wang Z, et al. Niflumic acid exhibits anti-tumor activity in nasopharyngeal carcinoma cells through affecting the expression of ERK1/2 and the activity of MMP2 and MMP9[J]. Int J Clin Exp Pathol, 2015, 8(9):9990-10001.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed